Abstract

Brucella is one of the most common bacterial zoonosis. Crimean-Congo Hemorrhagic Fever (CCHF) is a potentially life-threatening infection. They have similar epidemiologic and clinical presentations. A 40-year-old male patient, engaged in animal husbandry, presented to the emergency unit with complaints of weakness, headache, and fever. Because of his low platelet count, he was referred to the internal medicine clinic. The patient did not have a history of contact with a tick or a CCHF patient. The Brucella Rose Bengal Test (RBT) was performed and the result was positive. After he was referred to the infectious diseases clinic, the CCHF RT-PCR test was found to be positive and the Brucella Wright agglutination test was negative. The patient, who was diagnosed with CCHF, was discharged in good condition. A positive RBT result does not always make a definitive diagnosis of Brucella infection. In areas where CCHF and Brucella are endemic, CCHF should be considered even if there is no history of ticks.

Keywords: Brucellosis, Crimean-Congo hemorrhagic fever, Rose Bengal, thrombocytopenia

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Bozkurt Yavuz H. A case: Rose Bengal test positive Crimean Congo hemorrhagic fever patient. Northwestern Med J. 2023;3(3):197-200. https://doi.org/10.54307/NWMJ.2023.74046

References

  1. Mantur BG, Amarnath SK. Brucellosis in India - a review. J Biosci. 2008; 33(4): 539-47. https://doi.org/10.1007/s12038-008-0072-1
  2. Hayoun MA, Muco E, Shorman M. Brucellosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK441831/
  3. Christopher S, Umapathy BL, Ravikumar KL. Brucellosis: review on the recent trends in pathogenicity and laboratory diagnosis. J Lab Physicians. 2010; 2(2): 55-60. https://doi.org/10.4103/0974-2727.72149
  4. Ergönül O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006; 6(4): 203-14. https://doi.org/10.1016/S1473-3099(06)70435-2
  5. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone; 2005: 2669-74.
  6. Hatipoglu CA, Bulut C, Yetkin MA, et al. Evaluation of clinical and laboratory predictors of fatality in patients with Crimean-Congo haemorrhagic fever in a tertiary care hospital in Turkey. Scand J Infect Dis. 2010; 42(6-7): 516-21. https://doi.org/10.3109/00365540903582418
  7. Ciftçi C, Oztürk F, Oztekin A, et al. Comparison of the serological tests used for the laboratory diagnosis of brucellosis. Mikrobiyol Bul. 2005; 39(3): 291-9.
  8. Díaz R, Casanova A, Ariza J, Moriyón I. The Rose Bengal Test in human brucellosis: a neglected test for the diagnosis of a neglected disease. PLoS Negl Trop Dis. 2011; 5(4): e950. https://doi.org/10.1371/journal.pntd.0000950
  9. Ruiz-Mesa JD, Sánchez-Gonzalez J, Reguera JM, Martín L, Lopez-Palmero S, Colmenero JD. Rose Bengal test: diagnostic yield and use for the rapid diagnosis of human brucellosis in emergency departments in endemic areas. Clin Microbiol Infect. 2005; 11(3): 221-5. https://doi.org/10.1111/j.1469-0691.2004.01063.x
  10. Chothe SK, Saxena HM. Innovative modifications to Rose Bengal plate test enhance its specificity, sensitivity and predictive value in the diagnosis of brucellosis. J Microbiol Methods. 2014; 97: 25-8. https://doi.org/10.1016/j.mimet.2013.12.005
  11. Gemcioglu E, Erden A, Karabuga B, et al. False positivity of Rose Bengal test in patients with COVID-19: case series, uncontrolled longitudinal study. Sao Paulo Med J. 2020; 138(6): 561-2. https://doi.org/10.1590/1516-3180.2020.0484.03092020
  12. Solís García del Pozo J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS One. 2012; 7(2): e32090. https://doi.org/10.1371/journal.pone.0032090